Thyroid eye disease (Graves eye disease)

Thyroid eye disease, also known as Graves' ophthalmopathy, is an autoimmune inflammatory condition affecting the tissues around the eyes, including the muscles, fat, and connective tissues within the orbit. It is frequently associated with Graves' disease, which is the most common cause of an overactive thyroid gland. In this condition, the immune system mistakenly attacks both the thyroid gland and the orbital tissues, leading to inflammation and damage.

It is believed that in Graves' disease, autoantibodies produced against receptors in the thyroid gland also target similar receptors found in cells behind the eye. This binding triggers an inflammatory response, leading to the accumulation of certain substances, swelling, and thickening of the eye muscles and orbital fat. This process can push the eyeball forward, causing proptosis (eye bulging), and affect eye movement and function.

Symptoms can vary in severity and include redness or swelling of the conjunctiva, widening of the eyelid aperture, proptosis (bulging eyes), eyelid swelling and redness, pain behind the eyes and during eye movement, double vision (diplopia), and blurred vision. In more severe cases, corneal ulcers may develop due to increased exposure, severe impairment of eye movement, and even vision loss resulting from pressure on the optic nerve.

The primary risk factor for thyroid eye disease is smoking, which significantly increases both the risk and severity of the condition. Other factors include genetic predisposition and gender (women are more prone to developing the disease). Diagnosis involves a comprehensive eye examination by an ophthalmologist, assessment of optic nerve function, eye and eyelid position, and often imaging tests such as CT or MRI of the orbits to evaluate the extent of inflammation and structural changes.

Treatment for thyroid eye disease is complex and individualized, requiring collaboration between ophthalmologists, endocrinologists, and sometimes immunologists. It involves managing thyroid function, smoking cessation, and treating eye symptoms. Conservative treatments may include eye drops for dryness, ointments, and prism glasses to address double vision. In cases of active inflammation, corticosteroids or immunosuppressive medications may be used.

Surgery may be needed for persistent structural changes after the inflammatory phase has settled. Planned orbital decompression, strabismus surgery and eyelid surgery are generally timed for inactive, stable disease with thyroid function controlled. They can reduce eye bulging, improve alignment or improve eyelid closure. The operations are chosen and sequenced according to the patient's findings.

This timing differs when vision is threatened by optic nerve compression or severe corneal exposure. These complications require urgent specialist treatment, which may include orbital decompression during the active phase rather than waiting for the disease to settle.

Regular follow up with an ophthalmologist and endocrinologist is crucial for managing the disease. Urgent medical attention is required for sudden vision loss, changes in color vision, severe eye pain, or significant difficulty closing the eye. These symptoms may indicate serious complications such as optic nerve compression or dangerous corneal exposure, necessitating immediate medical intervention.